<\/span><\/h2>\nNOMID\/CINCA (MIM 607115) is the most severe and rare form of cryopyrin-associated periodic syndrome (CAPS). Although it is generally due to a single gene<\/span> mutation<\/span>, rarely, if ever, inherited, as it causes significant disabilities and is often fatal before adult life. It is called CINCA in Europe (where the syndrome was first described and studied in detail) and NOMID in the US.<\/p>\n<\/span>Who receives NOMID\/CINCA and why?<\/span><\/h2>\nNOMID\/CINCA is very rare autoinflammatory<\/span> syndrome, which occurs on or within days of birth. Signs can be detected in the brain in prenatal<\/span> ultrasound<\/span> before birth in severe cases. Birth is premature in a third of cases, and birth weight may be small for the dates.<\/p>\nNOMID\/CINCA is a autosomal<\/span> dominant condition, meaning that only a single copy of the defective gene is required to cause the clinical syndrome. A victim's child would have a 50% chance of inheriting the condition. However, it is not usually family<\/span> as it is fatal before adulthood or results in severe disabilities. Therefore, almost all reported cases are the result of spontaneous mutations<\/span>. This can change with successful treatment that now minimizes neurological <\/span>disability.<\/p>\n<\/span>\nMolecular<\/span> biology and genetics<\/span><\/h3>\nMutations in the NLRP3 gene are commonly identified in NOMID\/CINCA, therefore linking it to Muckle-Wells syndrome and familial cold-associated syndrome. Some mutations, such as Y570C, Y570F, F309S, and F523L, are unique to severe NOMID\/CINCA. Mild clinical features of NOMID\/CINCA are sometimes seen in patients with Muckle-Wells syndrome. Different overlapping characteristics can be seen even within a family. However, the severe clinical features of NOMID\/CINCA have never been reported in families with milder forms of CAPS.<\/p>\n
NOMID\/CINCA is likely to be a heterogeneous<\/span> (i.e. due to more than one genetic<\/span> defect) such as 40% cases do not have an identifiable mutation in the NLRP3 gene. However, there is no difference in response to anakinra treatment between those with or without NLRP3 mutations. It is likely that the mechanism of disease development involves overstimulation of interleukin<\/span>-1beta receiver<\/span> in all cases.<\/p>\n\n
\n
\n
\n<\/div><\/div><\/div><\/div>\n
<\/span>Clinical Features of NOMID\/CINCA<\/span><\/h2>\nClinical features of NOMID\/CINCA that differentiate it from the other forms of CAPS include presentation at birth or soon after, severe single joint changes, and chronic aseptic. meningitis<\/span> resulting in profound developmental delay and significant disability. As with all forms of CAPS, symptoms include skin eruption<\/span>, fever<\/span> and inflammation<\/span> of the eyes<\/p>\nNOMID\/CINCA symptoms tend to be constant, rather than episodic, with intermittent flares in activity. The clinical characteristics of NOMID\/CINCA are shown in the table below.<\/p>\n
\n\n\n| Symptom<\/span><\/th>\n | Description<\/th>\n<\/tr>\n |
\n| Fever<\/td>\n | \n\n- short episodes<\/li>\n
- \nRecurrent<\/span>\/intermittent<\/li>\n
- May be absent or very mild<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\n| Acne<\/td>\n | \n\n- Affects 100%<\/li>\n
- often the presenting feature<\/li>\n
- usually present at birth \u2013 75%<\/li>\n
- varies during the day, but tends to be always present<\/li>\n
- varies between patients and with severity of the disease outbreak<\/li>\n
- no itch urticarial<\/span>red migratory plates<\/span>\n<\/li>\n
- \nmaculopapular<\/span> rashes: may be locally persistent<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\n| Joint changes<\/td>\n | Early onset in the first year after birth: <\/p>\n\n- affects 33-50%<\/li>\n
- associated with serious illness<\/li>\n
- severe \u201covergrowth\u201d arthropathy<\/span>\n<\/li>\n
- enlargement of joints, for example, giant kneecap is characteristic<\/li>\n
- most common knees, followed by ankles, elbows, wrists<\/li>\n
- small joints in the hands and feet may also be involved<\/li>\n
- generally bilateral<\/span>\n<\/li>\n
- painful<\/li>\n
- \ncontractures<\/span> cause limited range of motion \u2013 a major cause of disability<\/li>\n
- Unique X-ray characteristic changes<\/li>\n
- due to uncontrolled overgrowth of the kneecap and the tips of the long bones with large abnormal bone masses in the joints<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\nLater start: <\/p>\n\n- half to two thirds<\/li>\n
- mild non-destructive arthropathy<\/li>\n
- mild transient swelling during an illness flare<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\n| Neurological<\/td>\n | Chronic aseptic meningitis: <\/p>\n\n- since childhood<\/li>\n
- almost all patients<\/li>\n
- can occur at birth or in the womb<\/span> how hydrocephalus<\/span> or ventriculomegaly<\/li>\n
- results in chronically elevated intracranial<\/span> pressure \u2013 chronic headaches, vomiting, ventriculomegaly, hydrocephalus, macromegaly, cerebral<\/span> atrophy<\/span>, optic atrophy<\/li>\n
- mental and developmental delay (50%)<\/li>\n
- seizures (25%)<\/li>\n
- leg spasticity \u2013 rare<\/li>\n
- \nhypotonia<\/span> - queer<\/li>\n
- transient hemiplegia \u2013 rare<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\nHearing loss: <\/p>\n\n- affects 75%<\/li>\n
- begins in late childhood<\/li>\n
- progressive<\/span><\/li>\n
- bilateral<\/li>\n
- perceptual sensorineural<\/span> deafness 20%<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\nEye problems: <\/p>\n\n- affected in at least 80%<\/li>\n
- \nincidence<\/span> of eye problems increases with age<\/li>\n
- average age of onset 4.5 years<\/li>\n
- \nuveitis<\/span> (previous<\/span> 50% later<\/span> 20%)<\/li>\n
- conjunctivitis<\/span><\/li>\n
- papillitis<\/li>\n
- optic atrophy can lead to vision loss: 25% in adults has significant visual impairment, including blindness<\/li>\n
- retinal vasculitis<\/span> - queer<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\n| Physical appearance<\/td>\n | \n\n- Prominent forehead<\/li>\n
- Flattening of the nasal bridge (saddled nose)<\/li>\n
- Big head (macrocephaly<\/span>) – 95%<\/li>\n
- large fontanelle<\/li>\n
- Short stature<\/li>\n
- Short and thick limbs<\/li>\n
- Finger clubbing<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\n| Other<\/td>\n | \n\n- Enlarged liver and spleen (hepatosplenomegaly<\/span>)<\/li>\n
- \nLymph node<\/span> enlargement (adenopathy)<\/li>\n
- \nUmbilical<\/span> cable<\/span> occasional anomalies<\/li>\n
- Delayed and secondary puberty amenorrhea<\/span>\n<\/li>\n
- Hoarseness: due to inflammation of the laryngeal cartilage<\/li>\n
- Secondary amyloidosis can develop with age.<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
20% dies before reaching adulthood, due to infection<\/span>, vasculitis and amyloidosis.<\/p>\n<\/span>How is NOMID\/CINCA diagnosed?<\/span><\/h2>\nNOMID-CINCA is characterized by the clinical triad of skin, joint, and neurological inflammation that occurs at or around the time of birth.<\/p>\n The clinical clues that should generate particular suspicions of the diagnosis in a child are:<\/p>\n \n- hydrocephalus or ventriculomegaly in a child with a normal number of chromosomes<\/span> and no history of birth asphyxia<\/li>\n
- posterior uveitis or optic disc edema<\/span>\n<\/li>\n
- \nyouth<\/span> arthritis<\/span>.<\/li>\n<\/ul>\n
The following table describes the results of the investigations.<\/p>\n \n\n\n| Proof<\/th>\n | recommendations<\/th>\n<\/tr>\n | \n| Blood test<\/td>\n | \n\n- increased white blood cells (leukocytosis<\/span>) \u2013 mild neutrophilia<\/li>\n
- elevated markers of inflammation: erythrocytes<\/span> sedimentation rate (ESR<\/span>) C-reactive protein<\/span> (CRP<\/span>) serum<\/span> amyloid<\/span> A (SAA)<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\n| X-rays<\/td>\n | \n\n- characteristic and exclusive of this syndrome<\/li>\n
- bone overgrowth due to premature ossification of the kneecap (patella) and epiphyses of the long bones<\/li>\n
- in very young children, bowing of long bones with periosteal reaction of widening and shortening<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\n| CSF<\/td>\n | \n\n- increased pressure increased proteins and inflammatory cells (neutrophils<\/span><\/span> 20-70% eosinophils<\/span> 0-30%) AND;<\/li>\n
- no evidence of virus infection, bacteria<\/span>, mycobacteria, yeasts or fungi<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\n| Skin biopsy<\/span>\n<\/td>\n | \n\n- \nneutrophilic<\/span> perivascular<\/span> dermal<\/span> infiltrate<\/span>\n<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\n| Audiometry<\/td>\n | \n\n- perceptual deafness<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\n| Ophthalmological evaluation<\/td>\n | \n\n- visual impairment due to optic atrophy<\/li>\n
- Visual field \u2013 enlargement of the blind spot of the retina<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\n| \nConnecticut<\/span> scan<\/td>\n | \n\n- can be normal<\/li>\n
- show mild cerebral atrophy \u2013 mild enlargement of the ventricles and subdural spaces<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\n| \nMagnetic resonance<\/span> with gadolinium<\/td>\n | \n\n- improvement of leptomeninges and cochlea<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n
\n| EEG<\/td>\n | \n\n- slow waves and punctual discharges<\/li>\n<\/ul>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
<\/span>NOMID\/CINCA Treatment<\/span><\/h2>\nAnakinra is a biological agent. It is a recombinant interleukin-1 receptor antagonist and the treatment of choice for NOMID\/CINCA. It is administered daily. subcutaneous<\/span> inyecci\u00f3n, rango de dosis 1-10mg \/ kg \/ d. Los ni\u00f1os muy peque\u00f1os parecen requerir una dosis mucho m\u00e1s alta por kg (6-10mg \/ kg \/ d) para control<\/span> s\u00edntomas y marcadores inflamatorios que los ni\u00f1os mayores o adultos (1-3 mg \/ kg \/ d). Debe iniciarse lo antes posible en la vida para minimizar las complicaciones neurol\u00f3gicas irreversibles. Es probable que el tratamiento contin\u00fae de por vida. Hasta ahora se han informado estudios con hasta 42 meses de tratamiento continuo. El tratamiento se inici\u00f3 a partir de los 3 meses de edad.<\/p>\nSe han informado dos grandes series de casos prospectivos, uno con 18 pacientes y el segundo con 10 beb\u00e9s, incluidos dos.<\/p>\n Se ha informado de mejoras en:<\/p>\n \n- S\u00edntomas cl\u00ednicos<\/li>\n
- Marcadores inflamatorios<\/li>\n
- Crecimiento: aumento de altura y peso si es prepuberal<\/li>\n
- La pubertad tard\u00eda y la amenorrea secundaria respondieron dentro de los 6 meses de tratamiento<\/li>\n
- Quality of life<\/li>\n
- Visi\u00f3n y audici\u00f3n<\/li>\n
- Presi\u00f3n intracraneal<\/li>\n
- Cambios de resonancia magn\u00e9tica en el o\u00eddo (inflamaci\u00f3n coclear) y leptomeninges (leptomeningitis)<\/li>\n<\/ul>\n
Pero no se observa mejor\u00eda en los cambios \u00f3seos que pueden continuar progresando. Las consecuencias de la amiloidosis secundaria, la sordera, la discapacidad visual, el retraso mental o el retraso del desarrollo existente pueden o persisten, permanecen estables o muestran una mayor progresi\u00f3n. La proteinuria puede mejorar, pero la insuficiencia renal puede ser estable. Evidencia de persistencia CNS<\/span> La inflamaci\u00f3n puede detectarse en el LCR como un aumento de prote\u00ednas y \/ o gl\u00f3bulos blancos y en la resonancia magn\u00e9tica. Aproximadamente un tercio mostr\u00f3 una mejora parcial en la p\u00e9rdida auditiva existente en los audiogramas, pero se observ\u00f3 deterioro en el 17% en una serie.<\/p>\nEn la primera serie, los 18 pacientes mostraron eliminaci\u00f3n de la erupci\u00f3n en 3 d\u00edas, y completaron remission<\/span> de cambios inflamatorios dentro de los 6 meses. Relapse<\/span> ocurri\u00f3 dentro de los 5 d\u00edas posteriores al cese de la anakinra. En la serie m\u00e1s reciente, los 10 pacientes tuvieron una remisi\u00f3n cl\u00ednica completa de fiebre, erupci\u00f3n cut\u00e1nea, dolor articular y muscular dentro de las 24 horas posteriores a la primera inyecci\u00f3n. La mejora se mantuvo, en todos los pacientes menos uno, durante todo el tratamiento durante 2-3.5 a\u00f1os. Sin embargo, los dos pacientes muy j\u00f3venes (el tratamiento comenz\u00f3 a los 3 y 4 meses de edad) mostraron reappearance<\/span> de s\u00edntomas 6-8 horas despu\u00e9s de la inyecci\u00f3n de dosis baja (1mg \/ kg \/ d) y requiri\u00f3 dosis divididas crecientes. Uno continu\u00f3 desarrollando erupciones cut\u00e1neas ocasionales asociadas con infecciones virales a pesar de una dosis de 10 mg \/ kg \/ d\u00eda. La persistencia de dolores de cabeza se correlacion\u00f3 con la presencia de papiledema y respondi\u00f3 al aumento de las dosis.<\/p>\nEn el estudio prospectivo de 18 pacientes con NOMID \/ CINCA, las reacciones locales en el lugar de la inyecci\u00f3n fueron las m\u00e1s comunes. adverse event<\/span>, con un aumento de las infecciones del tracto respiratorio superior. En la segunda serie de 10 pacientes, solo se informaron reacciones en el lugar de la inyecci\u00f3n. Los ni\u00f1os muy peque\u00f1os corren el riesgo de desarrollar infecci\u00f3n neumoc\u00f3cica debido a las dosis muy altas requeridas y su pobre respuesta inmune a encapsulated<\/span> bacterias Todos los pacientes deben ser inmunizados contra Streptococcus pneumoniae y Haemophilus influenzae antes de comenzar la terapia y se sugiere que se recete a ni\u00f1os muy peque\u00f1os. prophylactic<\/span> antibiotics<\/p>\nAnakinra tiene un gran impacto beneficioso en la calidad de vida de los pacientes con NOMID \/ CINCA. Si se comienza temprano en la vida, la anakinra puede prevenir la discapacidad causada por los cambios en las articulaciones y la inflamaci\u00f3n neurol\u00f3gica, sin embargo, se requiere un seguimiento m\u00e1s prolongado para confirmar esta impresi\u00f3n.<\/p>\n Nota: anakinra no est\u00e1 registrada ni subsidiada en Nueva Zelanda (marzo de 2011). En otros pa\u00edses, como los EE. UU. Y Europa, su indicaci\u00f3n registrada es la artritis reumatoide.<\/p>\n<\/section>","protected":false},"excerpt":{"rendered":" NOMID y CINCA son siglas alternativas para el mismo trastorno. NOMID: Neonatalmultisistema de inicio inflamatorio enfermedad CINCA Cr\u00f3nico neurol\u00f3gica infantil cut\u00e1neo y articular s\u00edndrome \u00bfQu\u00e9 es NOMID \/ CINCA? NOMID…<\/p>","protected":false},"author":8,"featured_media":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","format":"standard","meta":{"footnotes":""},"categories":[204],"tags":[],"class_list":["post-7699","wiki","type-wiki","status-publish","format-standard","category-glosario-definiciones"],"_links":{"self":[{"href":"https:\/\/doctorhoogstra.com\/en\/wp-json\/wp\/v2\/wiki\/7699","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/doctorhoogstra.com\/en\/wp-json\/wp\/v2\/wiki"}],"about":[{"href":"https:\/\/doctorhoogstra.com\/en\/wp-json\/wp\/v2\/types\/wiki"}],"author":[{"embeddable":true,"href":"https:\/\/doctorhoogstra.com\/en\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/doctorhoogstra.com\/en\/wp-json\/wp\/v2\/comments?post=7699"}],"version-history":[{"count":0,"href":"https:\/\/doctorhoogstra.com\/en\/wp-json\/wp\/v2\/wiki\/7699\/revisions"}],"wp:attachment":[{"href":"https:\/\/doctorhoogstra.com\/en\/wp-json\/wp\/v2\/media?parent=7699"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/doctorhoogstra.com\/en\/wp-json\/wp\/v2\/categories?post=7699"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/doctorhoogstra.com\/en\/wp-json\/wp\/v2\/tags?post=7699"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}} | | | | | | | | | | | | | | | | | |